by
Thomas Dworetzky, Contributing Reporter | January 24, 2018
IBM Watson Imaging Synopsis is a product slated for Q2 of 2018. It is designed to help radiologists navigate EMR/EHR information more efficiently, with relevant data rising to the top.
Another product, also slated for a 2018 release, is a “breast advisor,” according to Tolle, targeting a reduction of callbacks happening when women go for mammograms. The product is “using our algorithms to look at the current image, the prior image, calculate breast density, and we are showing the ability to prioritize a worklist based on potential pathology.”
Ad Statistics
Times Displayed: 41009
Times Visited: 663 Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.
One of the biggest challenges as AI moves into a hospital setting is the sheer number of companies and amount of money moving into the space. That surge of interest, Tolle believes, will favor IBM going forward.
The company has “pretty good experience in our enterprise imaging business, our consulting businesses, our platforms that we built as a business," noted Tolle. "So, I think you’ll see IBM and a couple of other companies act as consolidators in the business.”
Whether or not IBM's stake in health care will ultimately move the needle on its place among S&P 500 companies is something that only time will tell.
Back to HCB News
